{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:00:32Z","timestamp":1790190032386,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP223fa627005"],"award-info":[{"award-number":["JP223fa627005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["JP23wm0125008"],"award-info":[{"award-number":["JP23wm0125008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Moonshot R&D","award":["JPMJMS2025"],"award-info":[{"award-number":["JPMJMS2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mpox virus (MPXV) is the causative agent of mpox, a disease characterized by skin lesions, and remains a global threat since the recent 2022 outbreak. Tecovirimat is an antiviral agent that inhibits MPXV replication in vitro and in vivo by targeting the viral phospholipase VP37 protein and blocking viral envelope wrapping. Although tecovirimat has been administered to many mpox patients, the emergence of tecovirimat-resistant MPXVs carrying mutations in the VP37 protein has been reported, particularly in immunocompromised individuals. However, the impact of these respective mutations on drug susceptibility and viral fitness have not been fully characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tecovirimat was applied as a selective pressure in vitro to isolate MPXV variants carrying clinically observed VP37 substitutions. Drug susceptibility among the major VP37 mutations was compared, and the cellular fitness of the isolated viruses was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The VP37-N267D and -Y258C mutants showed markedly reduced susceptibility to tecovirimat compared with the VP37-I372N and -T245I (+I7L-A388S) mutants, while retaining susceptibility to an alternative anti-MPXV agent, brincidofovir. The VP37-I372N, T245I (+I7L-A388S), Y258C, and N267D mutants exhibited viral fitness comparable to that of the parental virus in A549 and Vero cells, as well as in MRC-5 and HaCaT cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings provide insights into the phenotype of each VP37 mutation and emphasize the importance of developing antivirals with distinct mechanisms of action to effectively combat tecovirimat-resistant MPXV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag222","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:30:44Z","timestamp":1778585444000},"page":"427-438","source":"Crossref","is-referenced-by-count":0,"title":["<i>In Vitro<\/i>\n                    Selection and Characterization of Tecovirimat-resistant Mpox Virus"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5751-863X","authenticated-orcid":false,"given":"Kei","family":"Konishi","sequence":"first","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd. , Osaka ,","place":["Japan"]},{"name":"Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7769-0412","authenticated-orcid":false,"given":"Haruka","family":"Maeda","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd. , Osaka ,","place":["Japan"]},{"name":"Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2623-7459","authenticated-orcid":false,"given":"Misato","family":"Shibazaki","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd. , Osaka ,","place":["Japan"]},{"name":"Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2549-0945","authenticated-orcid":false,"given":"Takao","family":"Shishido","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd. , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W","family":"Hall","sequence":"additional","affiliation":[{"name":"International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"National Virus Reference Laboratory, School of Medicine, University College of Dublin , Dublin ,","place":["Ireland"]},{"name":"Global Virus Network , Tampa, Florida ,","place":["USA"]},{"name":"Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-2175","authenticated-orcid":false,"given":"Michihito","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-3912","authenticated-orcid":false,"given":"Yasuko","family":"Orba","sequence":"additional","affiliation":[{"name":"Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2569-2755","authenticated-orcid":false,"given":"Hirofumi","family":"Sawa","sequence":"additional","affiliation":[{"name":"Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"Global Virus Network , Tampa, Florida ,","place":["USA"]},{"name":"Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"One Health Research Center, Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-1679","authenticated-orcid":false,"given":"Akihiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd. , Osaka ,","place":["Japan"]},{"name":"Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University , Sapporo ,","place":["Japan"]},{"name":"Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University , Sapporo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2026092314154605100_jiag222-B1","author":"World Health Organization"},{"key":"2026092314154605100_jiag222-B2","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S1473-3099(23)00427-9","article-title":"Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study","volume":"23","author":"Ogoina","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026092314154605100_jiag222-B3","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJMc2214921","article-title":"An mpox-related death in the United States","volume":"388","author":"Alarc\u00f3n","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092314154605100_jiag222-B4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(23)00273-8","article-title":"Mpox in people with advanced HIV infection: a global case series","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"The Lancet"},{"key":"2026092314154605100_jiag222-B5","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid3108.241551","article-title":"Emergence of clade ib monkeypox virus-current state of evidence","volume":"31","author":"Satheshkumar","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"2026092314154605100_jiag222-B6","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1016\/S2214-109X(23)00198-5","article-title":"Description of the first global outbreak of mpox: an analysis of global surveillance data","volume":"11","author":"Laurenson-Schafer","year":"2023","journal-title":"Lancet Global Health"},{"key":"2026092314154605100_jiag222-B7"},{"key":"2026092314154605100_jiag222-B8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728222.2023.2230361","article-title":"Potential therapeutic targets for mpox: the evidence to date","volume":"27","author":"Byrareddy","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"2026092314154605100_jiag222-B9","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1128\/jvi.65.11.5910-5920.1991","article-title":"Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein","volume":"65","author":"Blasco","year":"1991","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/jvi.68.1.130-147.1994","article-title":"Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network","volume":"68","author":"Schmelz","year":"1994","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B11","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jac\/dku545","article-title":"ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping","volume":"70","author":"Duraffour","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026092314154605100_jiag222-B13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14787210.2023.2170350","article-title":"Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential","volume":"21","author":"Russo","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026092314154605100_jiag222-B14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"key":"2026092314154605100_jiag222-B15","doi-asserted-by":"crossref","first-page":"eade7646","DOI":"10.1126\/scitranslmed.ade7646","article-title":"In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate","volume":"14","author":"Warner","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026092314154605100_jiag222-B16","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41564-022-01269-8","article-title":"Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations","volume":"7","author":"Frenois-Veyrat","year":"2022","journal-title":"Nat Microbiol"},{"key":"2026092314154605100_jiag222-B17","doi-asserted-by":"crossref","first-page":"e0056823","DOI":"10.1128\/aac.00568-23","article-title":"Identification of tecovirimat resistance-associated mutations in human monkeypox virus - Los Angeles county","volume":"67","author":"Garrigues","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314154605100_jiag222-B18","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3201\/eid2912.231146","article-title":"Tecovirimat resistance in mpox patients, United States, 2022-2023","volume":"29","author":"Smith","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2026092314154605100_jiag222-B19","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/infdis\/jiad517","article-title":"Surveillance of complicated mpox cases unresponsive to oral tecovirimat in Los Angeles county, 2022","volume":"229","author":"Karan","year":"2023","journal-title":"J Infect Dis"},{"key":"2026092314154605100_jiag222-B20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.15585\/mmwr.mm7340a3","article-title":"Notes from the field: mpox cluster caused by tecovirimat-resistant monkeypox virus - five states, October 2023-February 2024","volume":"73","author":"Gigante","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026092314154605100_jiag222-B21","doi-asserted-by":"crossref","first-page":"e28652","DOI":"10.1002\/jmv.28652","article-title":"Repurposing of the antibiotic nitroxoline for the treatment of mpox","volume":"95","author":"Bojkova","year":"2023","journal-title":"J Med Virol"},{"key":"2026092314154605100_jiag222-B22","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1128\/JVI.02642-05","article-title":"LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox","volume":"80","author":"Saijo","year":"2006","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B23","doi-asserted-by":"crossref","first-page":"e0018625","DOI":"10.1128\/aac.00186-25","article-title":"A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against la crosse virus infection","volume":"69","author":"Konishi","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314154605100_jiag222-B24","doi-asserted-by":"crossref","first-page":"eabq4064","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026092314154605100_jiag222-B25","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41564-025-01936-6","article-title":"Structural insights into tecovirimat antiviral activity and poxvirus resistance","volume":"10","author":"Vernuccio","year":"2025","journal-title":"Nat Microbiol"},{"key":"2026092314154605100_jiag222-B26","doi-asserted-by":"crossref","first-page":"e02154-17","DOI":"10.1128\/JVI.02154-17","article-title":"Vaccinia virus phospholipase protein F13 promotes rapid entry of extracellular virions into cells","volume":"92","author":"Bryk","year":"2018","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B27","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1128\/AAC.02814-14","article-title":"In vitro efficacy of brincidofovir against variola virus","volume":"58","author":"Olson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314154605100_jiag222-B28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2015.02.007","article-title":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease","volume":"117","author":"Trost","year":"2015","journal-title":"Antiviral Res"},{"key":"2026092314154605100_jiag222-B29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2017.04.002","article-title":"Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand white rabbits","volume":"143","author":"Grossi","year":"2017","journal-title":"Antiviral Res"},{"key":"2026092314154605100_jiag222-B30","doi-asserted-by":"crossref","first-page":"105995","DOI":"10.1016\/j.antiviral.2024.105995","article-title":"Treatment efficacy of cidofovir and brincidofovir against clade II monkeypox virus isolates","volume":"231","author":"Pr\u00e9vost","year":"2024","journal-title":"Antiviral Res"},{"key":"2026092314154605100_jiag222-B31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/dmd.122.000856","article-title":"Cell and tissue specific metabolism of nucleoside and nucleotide drugs: case studies and implications for precision medicine","volume":"51","author":"To","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"2026092314154605100_jiag222-B32","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S1473-3099(25)00014-3","article-title":"Antiviral activity of tecovirimat against monkeypox virus clades 1a, 1b, 2a, and 2b","volume":"25","author":"Postal","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026092314154605100_jiag222-B33","doi-asserted-by":"crossref","first-page":"132231","DOI":"10.1016\/j.ijbiomac.2024.132231","article-title":"Structural basis of human mpox viral DNA replication inhibition by brincidofovir and cidofovir","volume":"270","author":"Xu","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"2026092314154605100_jiag222-B34","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092314154605100_jiag222-B35","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.1128\/JVI.01528-08","article-title":"Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs","volume":"82","author":"Gammon","year":"2008","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B36","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1128\/JVI.00355-12","article-title":"Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus","volume":"86","author":"Duraffour","year":"2012","journal-title":"J Virol"},{"key":"2026092314154605100_jiag222-B37","doi-asserted-by":"crossref","first-page":"11094","DOI":"10.1074\/jbc.M115.709139","article-title":"Structure and metal binding properties of a poxvirus resolvase","volume":"291","author":"Li","year":"2016","journal-title":"J Biol Chem"},{"key":"2026092314154605100_jiag222-B38","doi-asserted-by":"crossref","first-page":"eadl1150","DOI":"10.1126\/sciadv.adl1150","article-title":"Essential and multifunctional mpox virus E5 helicase-primase in double and single hexamer","volume":"10","author":"Xu","year":"2024","journal-title":"Sci Adv"},{"key":"2026092314154605100_jiag222-B39","doi-asserted-by":"crossref","first-page":"13358","DOI":"10.1021\/acs.jmedchem.5c00019","article-title":"Discovery of small-molecule orthopoxvirus resolvase inhibitors with antiviral activity","volume":"68","author":"Mahoney","year":"2025","journal-title":"J Med Chem"},{"key":"2026092314154605100_jiag222-B40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41586-025-09014-x","article-title":"Substrate recognition and cleavage mechanism of the monkeypox virus core protease","volume":"643","author":"Gao","year":"2025","journal-title":"Nature"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag222\/68327133\/jiag222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/427\/68327133\/jiag222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/427\/68327133\/jiag222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:15:55Z","timestamp":1790187355000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/3\/427\/8686322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,18]]},"published-print":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag222","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,5,18]]}}}